Anna Wasiuk, Ph.D.
Affiliations: | 2010 | Immunology and Microbiology | Dartmouth College, Hanover, NH, United States |
Area:
Immunology, Cell BiologyGoogle:
"Anna Wasiuk"Parents
Sign in to add mentor| Randolph J. Noelle | grad student | 2010 | Dartmouth | |
| (Bridging the adaptive and innate immune system: A study on mast cells and the regulation of tumor immunity.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wasiuk A, Weidlick J, Sisson C, et al. (2021) Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice. Cancer Immunology, Immunotherapy : Cii |
| Vitale LA, He LZ, Thomas LJ, et al. (2020) Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii |
| Thomas LJ, He L, Gergel LE, et al. (2019) Abstract 3217: Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA Cancer Research. 79: 3217-3217 |
| Vitale LA, Thomas LJ, O'Neill T, et al. (2019) Abstract 2392: CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1 Cancer Research. 79: 2392-2392 |
| Alvarado D, Vitale L, Murphy M, et al. (2019) Abstract 1555: Monoclonal antibodies targeting the TAM family of receptor tyrosine kinases Cancer Research. 79: 1555-1555 |
| Thomas LJ, He L, Testa J, et al. (2018) Abstract 3816: Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models Cancer Research. 78: 3816-3816 |
| Wasiuk A, Testa J, Weidlick J, et al. (2017) CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. Journal of Immunology (Baltimore, Md. : 1950) |
| He L, Widger J, Testa J, et al. (2017) Abstract 3664: CDX-1402, a dendritic cell targeted fusion protein designed to elicit immunity to mesothelin and HER2 expressing tumors Immunology. 77: 3664-3664 |
| He L, Wasiuk A, Testa J, et al. (2015) The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent Journal For Immunotherapy of Cancer. 3: 188 |
| Thomas LJ, He L, Wasiuk A, et al. (2015) Abstract 253: Synergistic antitumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site Cancer Research. 75: 253-253 |